Published: Thu, September 01, 2016
Hi-Tech | By Ellis Neal

Preview of Stock Movement: Bristol-Myers Squibb Company (NYSE:BMY)


Forward Price to Earnings ratio of BMY attains value of 18.90 that is projecting or estimating EPS for the next 12-months and its follow by traders who believe on anticipates of a firm's future rather than past performance. According to a research note published on Aug 5, 2016, analysts at Morgan Stanley have lowered their rating on the company stock from Overweight to Equal-Weight.

Bristol-Myers Squibb Co (NYSE:BMY) remained bearish with a decrease -2.59% putting the price on the $57.24 per share in last trading session ended on 8/30/2016. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -6.26% where SMA50 and SMA200 are -16.96% and -14.33% respectively. The company has a market cap of $93.41 billion and the numbers of outstanding shares have been calculated to be 1.66 billion shares.

Bristol-Myers Squibb Company (BMY) and Pfizer Inc. This year Company's Earnings per Share (EPS) growth is -22.30% and next year's EPS growth is 15.13%. The company has a market cap of $98.48 billion. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million.

Historically the stock has slipped -0.88% in the past week and plunged -21.28% in the last four weeks, the stock illustrate that its three months performance stands at -17.15% while its year to date performance is at -13.60%.

Bristol-Myers Squibb Company has earnings per share of $ 1.71 and the earnings per share growth for this year is -22.30%.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. The float short ration was 0.64%; as compared to Short Ratio were 1.02. The ex-dividend date is Wednesday, October 5th.

Analysts' mean recommendation for Bristol-Myers Squibb Company's (BMY) stands at 2.50. Now shares have been rated as "Buy" from 3 Analysts. Deutsche Bank AG reaffirmed a "hold" rating on shares of Bristol-Myers Squibb in a report on Wednesday, June 15th.

05/23/2016 - Hilliard Lyons began new coverage on Bristol-Myers Squibb Company giving the company a "neutral" rating. Sell-side analyst recommendations point to a short term price target of $77.36 on the company shares.

In a related news, The director, of Bristol Myers Squibb Co, Andreotti Lamberto had unloaded 23,200 shares at $74.65 per share in a transaction on July 7, 2016. Also, the Hold rating count is 15 as of 8/31/2016.

The stock has received rating from many Reuters analysts. The company presently has a consensus rating of "Hold" and an average price target of $72.12. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors. The stock was sold at an average price of $59.17, for a total value of $1,372,744.00. This transaction occurred on 2016-06-28 totals $1673000.65. The shares were sold at an average price of $72.69, for a total value of $859,195.80.

Insiders own 0% percent of the stock. The disclosure for this sale can be found here.

The stats on Bristol-Myers Squibb Company are now as follows.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.

Like this: